Results 61 to 70 of about 13,617 (225)

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma

Journal of Allergy and Clinical Immunology: Global
Background: The cross-linking of FcεRI by IgE and allergen leads to the degranulation of basophils and mast cells, which can drive allergic reactions. Neutralizing IgE with omalizumab could thus offer clinical benefits to a subset of patients with asthma.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Matthew Wiest, PhD, Jacob Turner, PhD, HyeMee Joo, PhD, Mark Millard, MD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Omalizumab for successful chemotherapy desensitisation: What we know so far

Clinical and Translational Allergy, 2021
Background Hypersensitivity reactions induced by chemotherapeutic drugs may influence the course of the oncologic disease by preventing doctors from prescribing first‐line therapy.
Roxana Silvia Bumbacea, Selda Ali, Sabina Loredana Corcea, Luiza Spiru, Cornelia Nitipir, Victor Strambu, Dragos Bumbacea   +6 more
doaj   +1 more source

Omalizumab for management of refractory urticaria: Experience of a tertiary care centre in Eastern India

Indian Journal of Dermatology, 2018
Aim: To study the effects of omalizumab in chronic spontaneous urticaria in Indian patients. Setting and Design: The study was conducted in a tertiary care centre and it was retrospective and descriptive in nature.
Shekhar Neema, Manas Chatterjee
doaj   +1 more source

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Future Science OA, 2020
Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients
Laura Diluvio, Arianna Piccolo, Francesco Marasco, Laura Vollono, Caterina Lanna, Barbara Chiaramonte, Cinzia Niolu, Elena Campione, Luca Bianchi   +8 more
doaj   +1 more source

Omalizumab beyond asthma

, 2012
: Introduction: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids.
Echenique, Alejandro, Ramírez Giraldo, Ruth Helena, Sus Carrizosa, Sara, Sánchez Caraballo, Jorge Mario, Diez Zuluaga, Libia Susana, Olivares Gómez, María Margarita, Cardona Villa, Ricardo   +6 more
core   +1 more source

Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy &Rhinology, EarlyView.
Maxime Fieux, Philippe Gevaert, Leigh J. Sowerby   +2 more
wiley   +1 more source

Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry

Allergy, EarlyView.
Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...
Pavel Kolkhir, Pascale Salameh, Magdalena Zajac, Alicja Kasperska‐Zajac, Ana Giménez‐Arnau, Maria Puertolas, Hanna Bonnekoh, Carolina Vera Ayala, Michael Makris, Eleni Chatzidimitriou, Stamatios Gregoriou, Kanokvalai Kulthanan, Andrea Bauer, Mojca Bizjak‐Suran, Daria Fomina, Alexis Bocquet, Joachim Dissemond, Mohamed Abuzakouk, Tara Raftery, Nadine Chapman‐Rothe, Emek Kocatürk, Clive Grattan, Riccardo Asero, Jonny G. Peter, Simon Francis Thomsen, Karsten Weller   +25 more
wiley   +1 more source

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

Allergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier, Z. Abdul Hameed Ansari, A. H. Abdul Latiff, M. M. Abuzakouk, M. S. Agcaoili‐De Jesus, R. C. Agondi, M. Al‐Ahmad, A. A. Alangari, H. Alhameli, C. D. Alonso Bello, S. Alshareef, S. Al‐Tamemi, S. Altrichter, H. Al Wahshi, S. Aquilina, M. Araújo, R. Arnaout, R. Asero, B. Ballmer‐Weber, C. Bangert, A. Bauer, M. Ben‐Shoshan, J. A. Bernstein, C. Bindslev‐Jensen, M. Bizjak, I. Boccon‐Gibod, H. Bonnekoh, L. Bouillet, K. Brockow, Z. Brzoza, M. Bulatović Ćalasan, A. Bulkhi, T. Buttgereit, A. Bygum, T. Caballero, O. Calderon, R. Campos, M. Cancian, E. Carne, M. A. Castor, I. Cerecedo, T. Çetinarslan, I. Cherrez‐Ojeda, N. Chkhikvadze, H. J. Chong‐Neto, K. Choo, G. Christoff, C.‐Y. Chu, K. Ciupka, N. Conlon, C. Costa, T. Craig, P. Criado, I. Danilycheva, R. Darlenski, E. De Arruda Chaves, L. de Montjoye, M. S. Doutre, A. Du‐Thanh, D. Ebo, S. Elkhalifa, S. Elmariah, T. El‐Shanawany, L. F. Ensina, R. Ertaş, R. Fachini Jardim Criado, M. Ferrer, S. Ferrucci, J. S. Fok, D. Fomina, L. Fonacier, G. Fouda, I. Francescantonio, A. Fukunaga, C. A. Galvan Calle, E. Garcia, K. Gáspár, A. Gelincik, S. Geng, K. Godse, M. Gonçalo, M. Gotua, C. Grattan, M. Grosber, G. Guidos Fogelbach, M. Guilarte, R. Guillod, E. Hamelmann, J. Hawkes, K. Hayama, R. Heuer, M. Hide, W. Hoetzenecker, N. Inomata, H.‐R. Kang, A. Kaplan, A. Kapp, M. Karam, A. Kasperska‐Zajac, C. H. Katelaris, A. Kessel, M. Khoshkhui, B. Kim, T. Kinaciyan, E. Kocatürk, M. Kolacinska‐Flont, P. Kolkhir, G. N. Konstantinou, M. Kosnik, D. Krasowska, K. Kulthanan, M. S. Kumaran, I. Kuprys‐Lipinska, M. Labrador, J. I. Larco, D. Larenas‐Linnemann, E. Latysheva, E. Lazaridou, P. H. Li, H. Lima, U. Lippert, M. Magerl, M. Makris, J. Alves Marcelino, A. V. Marzano, I. Medina, R. Meshkova, D. Micallef, R. Mohammed Ali, C. G. Mortz, M. Munoz, H. N. G. Oude Elberink, A. Nakonechna, I. Nasr, A. Nast, E. Netchiporouk, E. Nettis, S. Nieto, I. Ogueta Canales, T.‐L. Okas, R. L. Orfali, E. Özkaya, C. Parisi, A. Pennitz, R. Pawankar, M. P. Pereira, J. Peter, E. Petkova, P. D. Pigatto, I. Podder, T. Popov, G. Porebski, P. Pyatilova, G. D. Ramon, H. A. Ratti Sisa, M. Recto, K. Ress, K. Ridge, M. Riedl, C. Ritchie, N. Rosario Filho, I. Rosmaninho, M. Rudenko, M. Rukhadze, K. Rutkowski, V. Sabato, U. M. Sahiner, S. Saini, F. Saleh Al Sabbagh, A. Salman, F. Salvo, J. Sanchez, A. Santucci, S. Schliemann, P. Schmid‐Grendelmeier, B. E. Sekerel, F. Serpa, F. Sheikh, J. Sheikh, H. Shendi, F. Siebenhaar, M. Sonomjamts, A. Soria, B. Sousa Pinto, M. Staevska, P. Staubach, M. Stephan, K. Stevanovic, L. Stingeni, M. Stobiecki, Ö. Su Küçük, G. Sussman, A. Szegedi, S. Takahagi, A. Tanaka, N. Teovska Mitrevska, S. F. Thomsen, E. Toubi, F. Tsatsou, M. Turk, Z. Vadasz, A. Valerieva, S. Valle, M. v. Doorn, B. Veleiro Perez, C. E. Vera Ayala, C. Vestergaard, R. J. Vieira, C. W. Maruta, B. Wedi, R. N. Werner, E. W. Y. Yap, P. Xepapadaki, Y. Xiang, Y.‐M. Ye, P. Yong, G. Yosipovitch, A. Z. J. Zalewska‐Janowska, C. Zeyen, Z. Zhao, M. Metz, A. M. Giménez‐Arnau   +221 more
wiley   +1 more source

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients

Indian Dermatology Online Journal, 2016
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H1-antihistamines.
Kiran Godse, Murlidhar Rajagopalan, Mukesh Girdhar, Sanjiv Kandhari, Bela Shah, Prashant N Chhajed, Sushil Tahiliani, D S Krupa Shankar, Vijay Somani, Vijay Zawar   +9 more
doaj   +1 more source